[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
IJRR Information::
For Authors::
For Reviewers::
News & Events::
Web Mail::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
Hard Copy 2322-3243
Online 2345-4229
Online Submission
Now you can send your articles to IJRR office using the article submission system.



:: Volume 21, Issue 4 (10-2023) ::
Int J Radiat Res 2023, 21(4): 679-684 Back to browse issues page
Monocyte-to-lymphocyte ratio as a prognostic indicator in head and neck squamous cell carcinoma treated with radiotherapy
H. Takano , H. Tanaka , T. Ono , M. Kajima , Y. Manabe , M. Matsuo
Department of Radiation Oncology Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan , htakano@gifu-u.ac.jp
Abstract:   (509 Views)
The monocyte-to-lymphocyte ratio (MLR) has been reported as a useful prognosticator in various types of cancers. We studied the usefulness of MLR as a prognosticator for head and neck squamous cell carcinoma (HNSCC) in patients with oropharyngeal, hypopharyngeal, and laryngeal cancer who received radical concurrent chemoradiotherapy (CRT) or bioradiotherapy (BRT). Materials and Methods: This study included 76 HNSCC patients diagnosed between January 2015 and April 2020. We obtained their haematological records within one month before radiotherapy and calculated the MLR. Kaplan-Meier method and Cox proportional hazard model were performed to evaluate the association of MLR with locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS). Results: The Kaplan–Meier survival analysis for MLR showed a significant difference (p = 0.0326) in OS. Univariate and multivariate analysis revealed that the lower MLR group was associated with better OS (hazard ratio [HR] = 0.345, 95 % confidence interval [CI] = 0.124–0.960, p = 0.042 and HR = 0.305, 95% CI = 0.102-0.916, p = 0.034, respectively). Multivariate analysis also revealed that N 2-3 was significant independent predictor of LFRS and PFS (HR = 4.47, 95% CI = 1.43–14.0, p = 0.0286 and HR = 4.94, 95% CI = 1.84-13.2, p < 0.01, respectively). Conclusion: MLR was useful as a prognostic predictor for OS in patients with HNSCC who received radical concurrent CRT or BRT. MLR may be more reflective of OS than of LRFS or PFS.
Keywords: Chemoradiotherapy, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Prognostic Factor, Radiotherapy.
Full-Text [PDF 570 kb]   (312 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, et al. (2018) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016. A systematic analysis for the global burden of disease study. JAMA Oncol, 4(11): 1553-68. [DOI:10.1200/JCO.2018.36.15_suppl.1568]
2. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. The Lancet, 371(9625): 1695-1709. [DOI:10.1016/S0140-6736(08)60728-X]
3. Blot WJ, McLaughlin JK, Winn DM, et al. (1988) Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res, 48: 3282-87.
4. Farshadpour F, Kranenborg H, Calkoen EV, et al. (2011) Survival analysis of head and neck squamous cell carcinoma: influence of smoking and drinking. Head and Neck, 33(6): 817-823. [DOI:10.1002/hed.21549] [PMID]
5. Giraldi L, Leoncini E, Pastorino R, et al. (2017) Alcohol and cigarette consumption predict mortality in patients with head and neck cancer: A pooled analysis within the International Head and Neck Cancer Epidemiology (INHANCE) Consortium. Ann Oncol, 28: 2843-2851. [DOI:10.1093/annonc/mdx486] [PMID] []
6. Cadoni G, Giraldi L, Petrelli L, et al. (2017) Prognostic factors in head and neck cancer: a 10-year retrospective analysis in a single-institution in Italy. Acta Otorhinolaryngol Ital, 37(6): 458. [DOI:10.14639/0392-100X-1246] [PMID] []
7. Cognetti DM, Weber RS, Lai SY (2008) Head and neck cancer: an evolving treatment paradigm. Cancer, 113(7): 1911- 1932. [DOI:10.1002/cncr.23654] [PMID] []
8. Jacobi I, Van Der Molen L, Huiskens H, et al. (2010) Voice and speech outcomes of chemoradiation for advanced head and neck cancer: a systematic review. Eur Arch Oto-Rhino-Laryngol, 267(10): 1495-1505. [DOI:10.1007/s00405-010-1316-x] [PMID] []
9. Guerriero JL (2018) Macrophages: the road less traveled, changing anticancer therapy. Trends Mol Med, 24: 472-489. [DOI:10.1016/j.molmed.2018.03.006] [PMID] []
10. Li W, Ma G, Wu Q, et al. (2017) Prognostic value of lymphocyte-to-monocyte ratio among Asian lung cancer patients: A systematic review and meta-analysis. Oncotarget, 8: 110606-110613. [DOI:10.18632/oncotarget.20574] [PMID] []
11. 11 Li W, Tao L, Zhang L, Xiu D (2017) Prognostic role of lymphocyte to monocyte ratio for patients with pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther, 10: 3391-3397. [DOI:10.2147/OTT.S142022] [PMID] []
12. Song W, Wang K, Zhang RJ, Zou SB (2016) Prognostic value of the lymphocyte monocyte ratio in patients with colorectal cancer: A meta-analysis. Medicine, 95: e5540. [DOI:10.1097/MD.0000000000005540] [PMID] []
13. 13 Lu C, Zhou L, Ouyang J, Yang H (2019) Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis. Medicine (Baltimore), 98: e15876. [DOI:10.1097/MD.0000000000015876] [PMID] []
14. Bonner JA, Harari PM, Giralt J, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol, 11: 21-8. [DOI:10.1016/S1470-2045(09)70311-0] [PMID]
15. Tang WH, Sun W, Long GX (2020) Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis. Medicine (Baltimore), 99(36): e21785. [DOI:10.1097/MD.0000000000021785] [PMID] []
16. Xun Y, Wang M, Sun H, et al. (2020) Prognostic analysis of preoperative inflammatory biomarkers in patients with laryngeal squamous cell carcinoma. Ear Nose Throat J, 99: 371-8. [DOI:10.1177/0145561319876910] [PMID]
17. Jiang R, Cai XY, Yang ZH, et al. (2015) Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. Chin J Cancer, 34(6): 237-246. [DOI:10.1186/s40880-015-0025-7] [PMID] []
18. Li J, Jiang R, Liu WS, et al. (2013) A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One, 8(12): e83069. [DOI:10.1371/journal.pone.0083069] [PMID] []
19. Kano S, Homma A, Hatakeyama H, et al. (2017) Pretreatment lymphocyte-to-monocyte ratio as an independent prognostic factor for head and neck cancer. Head Neck, 39(2): 247-253. [DOI:10.1002/hed.24576] [PMID]
20. Lu A, Li H, Zheng Y, et al. (2017) Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int, 2017: 3047802. [DOI:10.1155/2017/3047802] [PMID] []
21. Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant, 48(3): 452-458. [DOI:10.1038/bmt.2012.244] [PMID] []
22. Tham T, Olson C, Khaymovich J, et al. (2018) The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: A systematic review and meta-analysis. Eur. Arch. Oto-Rhino-Laryngol, 275:1663-1670. [DOI:10.1007/s00405-018-4972-x] [PMID]
23. Noy R and Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity, 41(1): 49-61. https://doi.org/10.1016/j.immuni.2014.09.021 [DOI:10.1016/j.immuni.2014.06.010]
24. Ostroumov D, Fekete-Drimusz N, Saborowski M, et al. (2018) CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci, 75:689-713. [DOI:10.1007/s00018-017-2686-7] [PMID] []
25. Xiang F, Chen R, Cao X, et al. (2018) Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study. Hemodial Int, 22: 82-92. [DOI:10.1111/hdi.12549] [PMID]
26. Cheng HR, Song JY, Zhang YN, et al. (2020) High monocyte-to-lymphocyte ratio is associated with stroke-associated pneumonia. Front. Neurol, 11: 575809. [DOI:10.3389/fneur.2020.575809] [PMID] []
27. Zhang M, Wang K, Zheng H, et al. (2020) Monocyte lymphocyte ratio predicts the new-onset of chronic kidney disease: a cohort study. Clin Chim Acta, 503: 181-189. https://doi.org/10.1016/j.aca.2020.03.010 https://doi.org/10.1016/j.cca.2019.11.021 [DOI:10.1016/j.aca.2019.11.012] [PMID]
28. Gao K, Zhu W, Liu W, et al. (2019) Diagnostic value of the blood monocyte-lymphocyte ratio in knee osteoarthritis. J Int Med Res, 47: 4413-4421. [DOI:10.1177/0300060519860686] [PMID] []
29. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature, 454(7203): 428-435. [DOI:10.1038/nature07201] [PMID]
30. Lin CH, Chou WC, Wu YY, et al. (2021) Prognostic significance of dynamic changes in lymphocyte-to-monocyte ratio in patients with head and neck cancer treated with radiotherapy: Results from a large cohort study. Radiother. Oncol, 154: 76-86. [DOI:10.1016/j.radonc.2020.09.012] [PMID]
31. Italiani P and Boraschi D (2014) From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Frontiers in Immunology, 5: 514. [DOI:10.3389/fimmu.2014.00514] [PMID] []
32. Komohara Y, Jinushi M, Takeya M (2014) Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci, 105(1): 1-8. [DOI:10.1111/cas.12314] [PMID] []
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Takano H, Tanaka H, Ono T, Kajima M, Manabe Y, Matsuo M. Monocyte-to-lymphocyte ratio as a prognostic indicator in head and neck squamous cell carcinoma treated with radiotherapy. Int J Radiat Res 2023; 21 (4) :679-684
URL: http://ijrr.com/article-1-5035-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 4 (10-2023) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4642